Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» BrainStorm Submits Favorable Interim Safety Report for Second Group of Patients in Its Phase IIa Dose-Escalating Trial of NurOwn in ALS
BrainStorm Submits Favorable Interim Safety Report for Second Group of Patients in Its Phase IIa Dose-Escalating Trial of NurOwn in ALS
BrainStorm Submits Favorable Interim Safety Report for Second Group of Patients in Its Phase IIa Dose-Escalating Trial of NurOwn in ALS
Submitted by
admin
on August 1, 2013 - 8:44am
Source:
Yahoo/MarketWire
News Tags:
BrainStorm Cell Therapeutics
Lou Gehrig's disease
ALS
stem cells
NurOwn
Headline:
BrainStorm Submits Favorable Interim Safety Report for Second Group of Patients in Its Phase IIa Dose-Escalating Trial of NurOwn in ALS
Do Not Allow Advertisers to Use My Personal information
